Hsp90 in Cancer: Beyond the Usual Suspects

1st Edition, Volume 129 - February 22, 2016
Editors: Jennifer Isaacs, Luke Whitesell
Language: English
Hardback ISBN:
9 7 8 - 0 - 1 2 - 8 0 2 2 9 0 - 0
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 0 2 4 8 3 - 6

Hsp90 in Cancer: Beyond the Usual Suspects, the latest volume in the Advances in Cancer Research series, focuses on the multifunctional molecular chaperone Hsp90 which regulat… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Hsp90 in Cancer: Beyond the Usual Suspects, the latest volume in the Advances in Cancer Research series, focuses on the multifunctional molecular chaperone Hsp90 which regulates the post-translational stability and function of a broad repertoire of client proteins and discusses some of the lesser-known aspects of how Hsp90 and its related family members enable oncogenic transformation and malignant progression.

Jennifer Isaacs

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA

Affiliations and expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA

Luke Whitesell

Luke Whitesell is a pediatric oncologist and senior research scientist at the Whitehead Institute. His clinical interests lie in the treatment of children with recurrent, refractory solid tumors. His laboratory efforts focus on the discovery and pre-clinical development of new anticancer drugs that target heat-shock proteins and the cellular heat-shock response. These ancient adaptive mechanisms act genome-wide to restore the normal protein folding environment within cells and enhance the survival of organisms under stress. In contrast to such well-recognized beneficial effects, however, they also enable cells to accommodate the drastic imbalances in signaling and profound alterations in DNA, protein and energy metabolism that occur in cancers. In essence, the malignant lifestyle confers a profound dependence on these “non-oncogenes”, strongly supporting the feasibility of targeting them to more effectively treat cancers. Building on these basic insights and the surprising ways in which HSP90 supports the evolution of new abilities in model organisms, a major goal of his current work is to test the idea that inhibiting HSP90 function can delay or prevent the evolution of a very undesirable trait in cancers, namely the acquisition of high level resistance to current chemotherapies.

Luke pursued graduate work in pharmacology at Cambridge University prior to completing medical training at Johns Hopkins University and residency at Boston Children’s Hospital. After fellowship training at the National Cancer Institute he joined the University of Arizona where he was Professor of Pediatric Oncology in the College of Medicine prior to taking his current position at the Whitehead Institute in Cambridge, MA.

Affiliations and expertise

Whitehead Institute for Biomedical Research, Cambridge, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health